A learned prostate-expression score associates with recorded progression
Source check: Source checked. Not independent scientific confirmation.
Finding: A CoxBoost and random-survival-forest score separated progression-free-survival groups across archived prostate-cancer datasets. Reported three-year AUCs ranged from 0.677 to 0.933 in the additional datasets. All those datasets informed final model selection, so they do not provide untouched external validation.
Technology: CoxBoost; random survival forest
Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.
- AI contribution
- CoxBoost and random survival forests fitted and selected a progression-related expression score; the learned model enables the represented survival association.
- Test and result
- The source trained on 494 TCGA records and considered 101 algorithm combinations. Five additional dataset groups, totaling 597 records as reported, were used to choose the best average concordance model. The final signature contained 13 genes.
- Limitation / still unknown
- The additional cohorts selected the final model, and group-specific median scores do not validate a fixed threshold. Cross-database patient independence and endpoint harmonization are not fully established. High training performance and retrospective associations do not establish calibrated clinical prediction, mast-cell causality or benefit from immunotherapy. Drug-sensitivity predictions are excluded.
Evidence sources and annotation context
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
Evidence sources: https://pmc.ncbi.nlm.nih.gov/articles/PMC11336432/ · https://www.ncbi.nlm.nih.gov/research/bionlp/RESTful/pmcoa.cgi/BioC_json/PMC11336432/unicode
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: not linked in this catalog; this does not mean no paper exists.
Review date: 21 Nov 2026. Review scope: Original primary computational model-selection and cohort survival Methods/Results only.
No follow-up recorded; this is not a claim that no follow-up exists. Follow-up review scope and date are not recorded. No source-supported relationships recorded.
Editorial assessment: Impact 1/5 · Validation 2/5 · Novelty 2/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.